A recently published review paper highlights TK1 as a tumor biomarker

Among other advantages the authors summarize that

• the immunoassay of TK1 makes it a more sensitive biomarker for studying solid malignancies, thereby increasing its value as a biomarker
• TK1 levels in malignancies are associated with clinical stage, offering potential for patient and subject stratification
• Elevated and/or increasing serum TK1 levels after treatment indicate therapy escape


Authors are Alertix Kiran Kumar Jagarlamudi and Martin Shaw.

Read more here